FDA Accepted Rani Therapeutics Into Technology Program

The regulatory body admitted the oral drug platform into its specialized Emerging Technology Program.

Updated on Oct. 5, 2026 in Biotech

FDA Accepted Rani Therapeutics Into Technology Program

Live Poll

Should the FDA provide early, collaborative support to companies developing novel pharmaceutical delivery technologies?

The FDA has accepted the RaniPill Capsule platform from Rani Therapeutics into its Emerging Technology Program. This initiative focuses on supporting novel manufacturing and design approaches for pharmaceutical products.

Why it matters

The program recognizes the RaniPill platform as a unique method for the oral delivery of biologics. Participation provides a formal pathway for the company to address regulatory considerations and refine its technology.

The RaniPill platform facilitates the oral delivery of biologics, a departure from traditional injection-based administration. The company aims to leverage FDA guidance to automate manufacturing processes for future clinical scale.

The players

Rani Therapeutics

Headquartered in San Jose, California, this firm develops specialized technology for the oral delivery of biologics.

FDA Emerging Technology Team

This body within the FDA works with developers to provide technical and regulatory feedback on innovative pharmaceutical product designs.

The details

Through the program, Rani Therapeutics will engage directly with the FDA Emerging Technology Team via pre-submission meetings and potential site visits. These interactions are designed to evaluate the underlying technology rather than specific drug products.

October 5, 2026: Rani Therapeutics announced its acceptance into the program.

Cancer
Sept. 30
Atara and Pierre Fabre Resubmitted Ebvallo to FDA
Cancer
Sept. 28
NeOnc Will Meet With FDA on November 17, 2026
Diabetes
Oct. 5
FDA Recommended Pre-BLA Meeting for Ersodetug

The Tech Race

The move reflects a broader industry shift toward transitioning complex biologic treatments from invasive injections to more accessible oral delivery methods. This transition marks a departure from traditional delivery legacy systems that have dominated the pharmaceutical market for decades.

Patients may eventually see improved accessibility to biologic therapies if the platform successfully automates production and clears clinical benchmarks. The regulatory engagement helps the company refine manufacturing, which is essential for ensuring product quality in mass-market applications.

The takeaway

The inclusion of the RaniPill platform in a specialized federal program underscores the importance of early regulatory collaboration for hardware-based medical innovation. Developers aiming to disrupt traditional drug delivery must navigate these rigorous oversight frameworks to ensure safety and scalability.